1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Amicogen, Inc.

Amicogen, Inc.

KKRX:092040
934.00
KRW
-6.00
(-0.64%)
-90.95EPS
114.49BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,128.93
732.74
845.75
1,722.81
1,823.99
2,271.77
3,063.25
2,781.51
2,962.94
3,368.76
4,006.94
3,160.27
760.89
762.6
Basic EPS, GAAP
1,022.42
202.76
53.83
39.68
-114.04
965.41
2.31
758.77
88.56
-1,102.4
-583.58
-961
-543
-79.71
Free Cash Flow per Basic Share
434.06
-26.63
130.79
-141.83
-22.9
-230.15
-356.63
-177.17
-1,166.02
-1,628.4
-1,352.17
-1,149.61
-511.03
-859.91
Dividend per Share
- -
- -
27.98
22.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,119.7
1,318.17
2,054.24
2,040.03
2,143.63
3,059.21
2,962.16
3,710.49
4,392.4
3,109.17
3,226.16
2,234.65
1,342.27
1,879.25
Tangible Book Value per Share
1,083.74
1,243.34
1,612.66
1,539.85
1,719.47
2,625.26
2,476.26
3,184.63
3,892.03
2,699.14
2,973.65
2,027.53
1,180.76
1,788.44
Basic Weighted Avg Shares
7
37
38
40
40
42
38
42
42
43
40
55
55
57
Sales/Revenue/Turnover
23,181
27,332
32,457
68,968
73,665
94,522
115,181
115,856
124,881
144,296
159,904
173,605
41,981
43,441
Operating Margin (%)
37.93
34.51
7.2
6.06
2.57
2.35
-1.9
2.68
-3.68
-3.39
0.04
-3.99
-36
-36.72
Depreciation Expense
982
1,283
2,417
5,275
8,111
7,994
10,053
10,000
10,771
12,665
13,264
13,954
9,631
9,959
Net Income, GAAP
7,575
7,563
2,066
1,589
-4,606
40,168
87
31,604
3,733
-47,220
-23,289
-52,791
-29,960
-4,541
Effective Tax Rate (%)
15.76
19.97
17.5
24.42
- -
21.99
- -
20.88
50.94
- -
- -
- -
- -
- -
Profit Margin (%)
32.68
27.67
6.36
2.3
-6.25
42.5
0.08
27.28
2.99
-32.72
-14.56
-30.41
-71.36
-10.45
Working Capital
26,371
26,393
34,904
19,526
27,202
21,933
26,468
39,467
-36,811
-61,222
-18,820
-11,407
-42,848
2,880
LT Debt
- -
- -
1,950
3,250
1,400
6,289
6,913
7,450
7,732
49,730
71,170
69,509
54,174
34,209
Total Equity
41,391
50,020
110,246
107,158
115,922
160,289
158,408
192,734
232,874
169,778
218,974
123,097
95,859
133,348
Return on Invested Capital (%)
23.34
16.13
2.07
2.38
- -
1.04
- -
1.12
-0.81
- -
- -
- -
- -
- -
Return on Capital (%)
24.82
16.69
2.02
1.49
- -
23.77
- -
14.73
1.51
- -
- -
- -
- -
- -
Return on Common Equity (%)
26.44
16.6
3.13
1.94
-5.4
37.11
0.07
22.99
2.2
-29.7
-15.14
-35.39
-27.6
-3.64

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
40,722
39,975
28,071
LT Borrowings
58,631
53,686
33,849
LT Finance Leases
600
488
360
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
70
70
Market Capitalization
212,774
125,548
114,487

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
42,657
37,858
44,103
Cash, Cash Equivalents & STI
11,523
7,242
7,813
Accounts Receivable, Net
8,722
8,595
14,278
Inventories
12,076
12,942
9,553
Total Current Liabilities
79,451
80,706
41,223
Payables & Accruals
- -
- -
- -
ST Debt
40,722
39,975
28,071
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.1%
-8.64%
-22.13%
Free Cash Flow
118.05%
109.38%
-55.35%
Net Income, GAAP
3,343.94%
-284.1%
-43.25%
Sales/Revenue/Turnover
13.7%
-6.62%
-75.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,178
42,674
39,899
56,853
173,605
2025
10,821
10,148
10,144
10,868
41,981
2026
12,280
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-101
-170
17
-708.79
-961
2025
-104
-109
-233.6
-96.25
-543
2026
318.69
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jjeo Pyo
Full Time Employees
228
Sector
Health technology
Industry
Biotechnology
Address
64, Dongbu-ro Jinju-si SG South Korea 52621
IPO Date
Sep 12, 2013
Website
amicogen.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Amicogen, Inc. Amicogen, Inc. (092040.KQ) operates as an industrial biotechnology company focused on developing, producing, and selling specialty enzymes, biopharmaceutical materials, and related products in South Korea and internationally. The company offers industrial and pharmaceutical-grade enzymes for various applications; chromatography resins and materials for purifying pharmaceutical proteins; cell culture media including classical media and CHO media for biopharmaceutical manufacturing; food-related additives; health functional foods such as those under the KAYNUTRA brand for lifelong healthcare; health and beauty products; oral treatments for incurable and rare diseases; and pharmaceutical raw materials including animal and human drugs. Incorporated in 2000 and headquartered in Jinju-si, South Korea, Amicogen serves biopharmaceutical contract development and manufacturing organizations (CDMOs), the food, cosmetics, and healthcare industries through its GMP-compliant facilities and smart production platforms. Recent developments include receiving KRW 7 billion in funding from BIFIDO Co., Ltd. in August 2025 to support growth initiatives; advancing a partnership with Lysando AG through share acquisition to develop Artilysin-based solutions against mastitis in dairy cows; and expanding bioprocessing capabilities with tailored cell culture media and OEM manufacturing services.